Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En fase III-undersøgelse af HMPL-760 i kombination med R-GemOx versus placebo i kombination med R-GemOx ved recidiveret/refraktær DLBCL

9. november 2026 opdateret af: Hutchmed

En fase III randomiseret, dobbeltblind, positiv kontrolleret undersøgelse til vurdering af effekt, sikkerhed og farmakokinetik af HMPL-760 i kombination med R-GemOx versus placebo i kombination med R-GemOx hos patienter med recidiverende/refraktær diffust storcellet B-cellelymfom (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

240

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Baoding, Kina
        • Rekruttering
        • Baoding NO.1 Central Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Haiying Yao
      • Beijing, Kina
        • Rekruttering
        • Beijing GoBroad Hospital
        • Ledende efterforsker:
          • Kai Hu
        • Kontakt:
      • Beijing, Kina
        • Rekruttering
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Ledende efterforsker:
          • Liang Wang
        • Kontakt:
      • Bengbu, Kina
        • Rekruttering
        • The First Affiliated Hospital of Bengbu Medical College
        • Kontakt:
        • Ledende efterforsker:
          • Yanli Yang
      • Changchun, Kina
        • Rekruttering
        • The First Hospital of Jilin University
        • Ledende efterforsker:
          • Ou Bai
        • Kontakt:
      • Changsha, Kina
        • Rekruttering
        • Hunan Cancer Hospital
        • Ledende efterforsker:
          • Hui Zhou
        • Kontakt:
      • Changsha, Kina
        • Rekruttering
        • The Second Xiangya Hospital of Central South University
        • Ledende efterforsker:
          • Hongling Peng
        • Kontakt:
      • Changsha, Kina
        • Rekruttering
        • People's Hospital of Hunan Province
        • Kontakt:
        • Ledende efterforsker:
          • Can Liu
      • Chengdu, Kina
        • Rekruttering
        • West China Hospital of Sichuan University
        • Ledende efterforsker:
          • Liqun Zou
        • Kontakt:
      • Chengdu, Kina
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xiaobing Huang
      • Chongqing, Kina
        • Rekruttering
        • The First Affiliated Hospital of Chongqing Medical University
        • Ledende efterforsker:
          • Xin Wang
        • Kontakt:
      • Chongqing, Kina
        • Rekruttering
        • Chongqing University Cancer Hospital
        • Ledende efterforsker:
          • Yao Liu
        • Kontakt:
      • Fujian, Kina
        • Rekruttering
        • Quanzhou First Hospital.Fujian
        • Kontakt:
        • Ledende efterforsker:
          • Xiongpeng Zhu
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Ledende efterforsker:
          • Jianzhen Shen
        • Kontakt:
      • Guangzhou, Kina
        • Rekruttering
        • Sun Yat-sen University Cancer Center
        • Ledende efterforsker:
          • Zhiming Li
        • Kontakt:
      • Guangzhou, Kina
        • Rekruttering
        • Guangdong Provincial People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xiaojuan Wei
      • Guangzhou, Kina
        • Rekruttering
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Ledende efterforsker:
          • Yuhua Li
        • Kontakt:
      • Guiyang, Kina
        • Rekruttering
        • The Affiliated Hospital of Guizhou Medical University
        • Ledende efterforsker:
          • Yan Zhang
        • Kontakt:
      • Hangzhou, Kina
        • Rekruttering
        • Zhejiang Cancer Hospital
        • Ledende efterforsker:
          • Haiyan Yang
        • Kontakt:
      • Hangzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital, Zhejiang University
        • Ledende efterforsker:
          • Zhen Cai
        • Kontakt:
      • Harbin, Kina
        • Rekruttering
        • Harbin Medical University Cancer Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Qingyuan Zhang
      • Hefei, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Anhui Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Zhimin Zhai
      • Jinan, Kina
        • Rekruttering
        • Qilu Hospital of Shandong University
        • Kontakt:
        • Ledende efterforsker:
          • Shuqian Xu
      • Jinan, Kina
        • Rekruttering
        • Shandong Cancer Hospital & Institute
        • Ledende efterforsker:
          • Zengjun Li
        • Kontakt:
      • Kunming, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Mingxia Shi
      • Nanchang, Kina
        • Rekruttering
        • Jiangxi Cancer Hospital
        • Ledende efterforsker:
          • Yan Huang
        • Kontakt:
      • Nanjing, Kina
        • Rekruttering
        • Jiangsu Cancer Hospital
        • Ledende efterforsker:
          • Yan Zhang
        • Kontakt:
      • Nanjing, Kina
        • Rekruttering
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Kontakt:
        • Ledende efterforsker:
          • Jingyan Xu
      • Nanning, Kina
        • Rekruttering
        • The First Affiliated Hospital of Guangxi Medical University
        • Ledende efterforsker:
          • Zhigang Peng
        • Kontakt:
      • Qingdao, Kina
        • Rekruttering
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
        • Ledende efterforsker:
          • Xia Zhao
      • Shanghai, Kina
        • Rekruttering
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Ledende efterforsker:
          • Weili Zhao
        • Kontakt:
      • Shanghai, Kina
        • Rekruttering
        • Tongji Hospital of Tongji University
        • Kontakt:
        • Ledende efterforsker:
          • Ping Li
      • Shanghai, Kina
        • Ikke rekrutterer endnu
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Ledende efterforsker:
          • Ligen Liu
        • Kontakt:
      • Shenyang, Kina
        • Rekruttering
        • Shengjing Hospital of China Medical University
        • Ledende efterforsker:
          • Wei Yang
        • Kontakt:
      • Shenzhen, Kina
        • Rekruttering
        • Shenzhen people's hospital
        • Ledende efterforsker:
          • Jihao Zhou
        • Kontakt:
      • Taiyuan, Kina
        • Rekruttering
        • Shanxi Provincial Cancer Hospital
        • Ledende efterforsker:
          • Liping Su
        • Kontakt:
      • Tangshan, Kina
        • Rekruttering
        • North China University of Science and Technology Affiliated Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Zhenyu Yan
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Medical University Cancer Institute & Hospital
        • Ledende efterforsker:
          • Zhengzi Qian
        • Kontakt:
          • Zhengzi Qian
          • Telefonnummer: 13702031222
          • E-mail: qzz@163.com
      • Tianjin, Kina
        • Rekruttering
        • Tianjin People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xingli Zhao
      • Tianjin, Kina
        • Rekruttering
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Ledende efterforsker:
          • Dehui Zou
        • Kontakt:
      • Wenzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of WMU
        • Kontakt:
        • Ledende efterforsker:
          • Songfu Jiang
      • Wuhan, Kina
        • Rekruttering
        • Hubei Cancer Hospital
        • Ledende efterforsker:
          • Huijing Wu
        • Kontakt:
      • Wuhan, Kina
        • Rekruttering
        • Wuhan Union Hospital of China
        • Ledende efterforsker:
          • Liling Zhang
        • Kontakt:
      • Xi'an, Kina
        • Rekruttering
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Ledende efterforsker:
          • Pengcheng He
        • Kontakt:
      • Xi'an, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Ledende efterforsker:
          • Jie Liu
        • Kontakt:
      • Xiamen, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Xiamen University
        • Ledende efterforsker:
          • Bing Xu
        • Kontakt:
      • Xuzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Xuzhou Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Wei Sang
      • Zhengzhou, Kina
        • Rekruttering
        • Henan Cancer Hospital
        • Ledende efterforsker:
          • Keshu Zhou
        • Kontakt:
      • Zhengzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
        • Ledende efterforsker:
          • Xudong Zhang
      • Ürümqi, Kina
        • Rekruttering
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Ledende efterforsker:
          • Yan Li
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekruttering
        • Fudan University Shanghai Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Fangfang Lv

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andre navne:
  • Gemcitabinhydrochlorid til injektion
  • Rituximab injektion
  • Oxaliplatin Injektion
Placebo komparator: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andre navne:
  • Gemcitabinhydrochlorid til injektion
  • Rituximab injektion
  • Oxaliplatin Injektion

Patients will receive HMPL-760 placebo once daily (QD) orally.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Tidsramme: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Tidsramme: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Tidsramme: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Tidsramme: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Tidsramme: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Independent review committee (IRC)-assessed PFS
Tidsramme: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Tidsramme: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Tidsramme: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Tidsramme: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Tidsramme: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Tidsramme: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Tidsramme: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Tidsramme: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Biomarker assessment
Tidsramme: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Tidsramme: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Weili Zhao, Ruijin Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. marts 2026

Primær færdiggørelse (Anslået)

30. april 2028

Studieafslutning (Anslået)

30. december 2028

Datoer for studieregistrering

Først indsendt

28. januar 2026

Først indsendt, der opfyldte QC-kriterier

6. februar 2026

Først opslået (Faktiske)

13. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .